CD33 and acute myeloid leukemia: Although GO is effective in some patients, the importance of evaluating the association between CD33 genotypes of the most significant SNPs such as c.205A>G (rs2455069), c.529G>A (rs35112940), c.532T>C (rs61736475), c.*201G>C (rs1803254), c.466_469del (rs201074739) and CD33 cell surface expression levels in AML patients is noted to obtain a prediction of patient response on GO treatment [92].